Author: Shen, Yue; Eades, William; Yan, Bingfang
Title: The COVIDâ€19 medicine remdesivir is therapeutically activated by carboxylesteraseâ€1 AND excessive hydrolysis increases cytotoxicity Cord-id: pjbgwhbh Document date: 2021_4_21
ID: pjbgwhbh
Snippet: The pandemic of coronavirus disease 2019 (COVIDâ€19) has become a global health crisis with the death toll of over 14 million people. So far, there are limited options to treat COVIDâ€19. Remdesivir was granted emergency use authorization earlier, and full use recently. Remdesivir was originally developed against Ebola viral infection and has since been shown to exert a broad antiviral activity against as many as seven viral families [1]. On the other hand, serious adverse events and mortality
Document: The pandemic of coronavirus disease 2019 (COVIDâ€19) has become a global health crisis with the death toll of over 14 million people. So far, there are limited options to treat COVIDâ€19. Remdesivir was granted emergency use authorization earlier, and full use recently. Remdesivir was originally developed against Ebola viral infection and has since been shown to exert a broad antiviral activity against as many as seven viral families [1]. On the other hand, serious adverse events and mortality remained high even with remdesivir among COVIDâ€19 patients [2â€4].
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date